Search Results

Amprion is pleased to announce its presence at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders in Lisbon, Portugal on March 5-9.

Amprion has been contracted by the National Institutes of Health Intramural Research Program’s Center for Alzheimer’s and Related Dementias to study the levels of misfolded alpha-synuclein proteins in people with Alzheimer’s disease.

Amprion, a global leader in neurodegenerative disease diagnostics, continues to fortify its Intellectual Property surrounding the company’s proprietary methodology for highly sensitive detection of misfolded proteins and amyloid-like aggregates.

Amprion, a global leader in the advancement of neurodegenerative disorder diagnosis, will be in attendance at the Alzheimer’s Association International Conference® 2023 in Amsterdam on July 16-20.

Amprion is pleased to announce its attendance at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders in Gothenburg, Sweden on March 28-April 1.

Amprion is pleased to announce that it will attend the American Academy of Neurology (AAN) Annual Meeting in Boston April 22-27 to share insights about its SYNTap Biomarker Test, a first-in-class qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid physicians in diagnosing synucleinopathies.

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.